Japan· JP-3969009F1015
ミグリトール
A miglitol product containing ミグリトール, registered in Japan, on the national reimbursement list. The same ATC class is registered in 2 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Miglitol is registered in 2 of 19 countries.
Countries holding a registration under ATC A10BF02 (miglitol), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 1 of them publish a price we can compare per daily dose
Miglitol · ATC A10BF02
2 / 19 countries
- Japan
- United Statesprice
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- ミグリトール
- Manufacturer
- —
- Country
- Japan (JP)
- ATC code
- A10BF02
- ATC class
- Miglitol
- Defined daily dose
- 0.3 g, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
302 interactions on record for miglitol.
Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Miglitol · interactions on record
302 records
- 1 severe
- 258 moderate
- 43 minor
Most severe, free to view
- GatifloxacinJ01MA16severe
- SucralfateA02BX02moderate
- ThiethylperazinA04AB03moderate
- TriflupromazinA04AD06moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Miglitol in 1 other country
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ce2c7aff-1035-4ed8-9c51-459d4be831cc GET /v1/drugs/ce2c7aff-1035-4ed8-9c51-459d4be831cc?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "２５ｍｇ１錠",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "3969009F1015",
"category": "内用薬",
"price_yen": 10.8,
"generic_name": "ミグリトール",
"product_name_jp": null,
"therapeutic_class": "3969",
"transitional_expiry": null
}See everything about miglitol.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.